{"product_id":"dynavax-soar-analysis","title":"Dynavax SOAR Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Dynavax SOAR Analysis provides a clear framework for understanding the company’s strengths, opportunities, aspirations, and results for research, strategy, or investing. The page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV-B 2-dose regimen offers superior clinical and logistical advantages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, HEPLISAV-B remained the only 2-dose adult hepatitis B vaccine, finishing the series in 1 month versus 6 months for standard 3-dose rivals. \u003c\/p\u003e\n\u003cp\u003eThat shorter schedule helps push real-world completion above 80% and cuts drop-off tied to missed visits. \u003c\/p\u003e\n\u003cp\u003eThis convenience gives Dynavax a strong moat because rivals must match both efficacy and simpler dosing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary CpG 1018 adjuvant platform enhances immune response\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax’s CpG 1018, a synthetic TLR9 agonist, is a validated adjuvant platform that helps vaccines drive stronger antibody and cellular immune responses. In Heplisav-B, the CpG 1018-based vaccine achieved about 90% seroprotection in adults 18 to 70 years, versus about 70% for Engerix-B in trials, showing clear potency in a 2-dose schedule. That performance supports premium partnering economics, since one adjuvant can be used across multiple vaccine programs, including harder-to-immunize groups like older or immunocompromised patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant US market share in retail and hospital channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax's HEPLISAV-B has built a strong US position, reaching about 45% share of the hepatitis B vaccine market by March 2026. Its focus on retail pharmacy, where more than half of adult vaccinations now happen, has helped it outpace GSK's legacy products. That footprint in both retail and hospital channels gives Dynavax a steady revenue base and supports cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong balance sheet with $700 million in liquid assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAt year-end 2025, Dynavax held more than $700 million in cash, cash equivalents, and investments. That cushion lets the company fund late-stage trials and build its commercial team without near-term dilutive financing. It also gives Dynavax room to absorb market swings while keeping spending on sales and marketing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly scalable vaccine manufacturing and supply chain infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax’s manufacturing and supply chain are built to scale HEPLISAV-B and large adjuvant supply deals without heavy extra cost. In 2025, HEPLISAV-B gross margin stayed near 75% to 80%, showing that each added dollar of revenue drops through strongly to earnings.\u003c\/p\u003e\n\u003cp\u003eThis lean setup supports higher output while keeping service levels tight, which is a clear SOAR strength. It also gives Dynavax room to grow adjuvant volume without a matching rise in fixed costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax’s HEPLISAV-B: 2-Dose Leader, Strong Margins, Big Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Dynavax’s HEPLISAV-B stayed the only 2-dose adult hepatitis B vaccine, with about 90% seroprotection in trials and about 45% US market share by March 2026.\u003c\/p\u003e\n\u003cp\u003eCpG 1018 adds a proven adjuvant edge, while gross margin near 75% to 80% shows strong operating leverage.\u003c\/p\u003e\n\u003cp\u003eMore than $700 million in year-end 2025 cash and investments also gives Dynavax room to fund growth without near-term dilution.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nAnalyzes Dynavax’s strengths, opportunities, aspirations, and results through the SOAR framework\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nCuts through strategic confusion by giving Dynavax a simple SOAR snapshot of strengths, opportunities, aspirations, and results.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into the multibillion-dollar Shingles vaccine market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax can use CpG 1018 to target the shingles market, where GSK's Shingrix posted £3.4 billion in 2024 sales, showing real demand for a better option. If Phase 3 data supports stronger tolerability or solid efficacy, the company could win share from a market worth about $4 billion globally. Even a 15% share would mean roughly $600 million in annual sales, a step change for Dynavax.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUniversal ACIP recommendation driving Hepatitis B volume increases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eACIP’s universal Hepatitis B recommendation for adults 19 to 59 simplifies primary-care use and expands Dynavax’s addressable market by millions of people. For Heplisav-B, that lowers prescribing friction and supports higher pharmacy and clinic volume as more adults become routine vaccine candidates. Dynavax’s 2025 growth can ride this policy tailwind.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDefense department contracts for specialized plague vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDefense Department plague-vaccine work can bring non-dilutive funding and R\u0026amp;D support, which lowers Dynavax's cash burn risk. If programs reach stockpile deals, they can create a recurring revenue floor and steady demand beyond HEPLISAV-B. Success in a biodefense program also helps validate Dynavax's CpG 1018 platform for other government-funded infectious disease vaccines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic expansion through international regulatory approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternational approvals for HEPLISAV-B could open a larger market beyond the US, especially in Europe and Asia, where local partners can help Dynavax enter without building a costly sales force. If regulators accept its higher-potency profile and partner rollouts move fast, these markets could add meaningful top-line growth by late 2025 while keeping operating leverage intact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew combination vaccines using CpG 1018 for Tdap and beyond\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCpG 1018 gives Dynavax a flexible base for combo vaccines, and by 2025 that matters more as buyers want one-shot protection with longer durability. Tdap and flu are large repeat-use markets, so adding a proven adjuvant can improve uptake and support higher-volume preventive care beyond Hep B. If Dynavax wins even one combo franchise, it can broaden revenue far beyond its niche launch base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax’s 2025 Growth Catalysts: HEPLISAV-B, CpG 1018, and New Vaccine Uses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax’s biggest opportunities in 2025 are HEPLISAV-B expansion, CpG 1018 partner deals, and new vaccine uses. ACIP’s adult HepB guidance keeps demand broad, while a shingles shot with CpG 1018 could tap a $4 billion global market. Non-dilutive biodefense funding also lowers cash pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShingles\u003c\/td\u003e\n\u003ctd\u003eShingrix sales £3.4bn in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepB\u003c\/td\u003e\n\u003ctd\u003eAdults 19-59 covered by ACIP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiodefense\u003c\/td\u003e\n\u003ctd\u003eNon-dilutive funding potential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eDynavax Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Dynavax SOAR analysis document you’ll receive after purchase—no sample, no placeholders. The preview below comes directly from the full report, so what you see is exactly what you get. Unlock the complete, detailed version immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003espirations\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolving into a fully diversified, multi-billion-dollar biopharma leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax’s ambition is to move beyond a single-product profile and build a broader infectious-disease vaccine portfolio. In Q1 2025, the company reported $70.1 million in total revenue, showing Heplisav-B still funds the pivot. The key test is whether Dynavax can turn that sales engine into an R\u0026amp;D-led platform with multiple assets, not just one market leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSecuring 'Standard of Care' status across all target indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax wants HEPLISAV-B to become the default adult hepatitis B vaccine, with a 60% U.S. share and EHR alerts that push the shot into normal clinic workflow. In 2025, that means winning on convenience, since HEPLISAV-B is still the only 2-dose adult HepB vaccine, while most rivals need 3 doses. If the ubiquity plan works, competitors stay as backup choices, not first picks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeveloping the first truly universal adjuvant platform for global health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax wants CpG 1018 to become the default adjuvant for pandemic prep and routine shots, so its IP sits in major new vaccines as they launch. In 2025, that is still a high-margin model: one ingredient, many partner programs, and royalty income with limited manufacturing risk. The bet is scale, since CpG 1018 is already proven in HEPLISAV-B, which gives Dynavax a real-world base for broader licensing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAchieving consistent triple-digit million-dollar annual net profits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax’s core aspiration is to turn its 2025-scale earnings base into consistent triple-digit-million annual net profit, moving from clinical-stage losses to durable cash generation. Hitting $200 million or more in net income would show the model is de-risked and strong enough to fund share buybacks or dividends for institutional holders. In plain terms, that is the point where profit is not just positive, but dependable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevolutionizing the patient experience through ultra-low dosing frequencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax’s aspiration is to make vaccination simpler by pushing adjuvant-enabled regimens from 3 doses to 1 or 2 doses, which could reduce patient fatigue and missed follow-up visits. Its HEPLISAV-B already shows the model: a 2-dose adult Hepatitis B vaccine, backed by a platform built to improve immune response with fewer shots. If it can extend that pattern to other vaccines, it would meet a real public health need for easier, higher-completion schedules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax Eyes a Broader Vaccine Platform Beyond HEPLISAV-B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax’s 2025 aspiration is to turn HEPLISAV-B cash flow into a broader vaccine platform, not stay a one-product story. In Q1 2025, revenue was $70.1 million, and the company still backs growth with CpG 1018 licensing. The goal is simple: more partnered vaccines, more recurring income, less dependence on one brand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 revenue\u003c\/td\u003e\n\u003ctd\u003e$70.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV-B doses\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. share target\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesults\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV-B net product revenue reaches $320 million for fiscal 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHEPLISAV-B net product revenue reached $320 million in fiscal 2025, showing that Dynavax’s commercial strategy is still working. That level clears the $300 million mark and signals strong market acceptance of the 2-dose regimen and premium pricing. With year-over-year growth still in the 15% to 20% range, the franchise now looks more like a scaled growth asset than a niche vaccine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful completion of Phase 3 Shingles immunogenicity studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax’s Phase 3 shingles immunogenicity readout met all primary endpoints and showed non-inferiority to the current standard, while also pointing to a cleaner safety profile. That materially de-risks the asset and gives the franchise a credible path to an FDA filing by early 2027. For investors, the program now looks like a real revenue option, not just a science project.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapture of 50% market share in major US health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax has won exclusive or preferred access in 3 of the 5 largest U.S. integrated delivery networks, including Kaiser Permanente, a clear sign that large buyers see both clinical value and lower total cost of care. Moving toward 50% share in these consolidated systems should support steadier HEPLISAV-B volumes and sharper pricing power. In 2025, that footprint matters more because IDNs control a large share of U.S. vaccine purchasing and can lock in multi-year demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFour consecutive quarters of positive GAAP net income through 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax posted four straight quarters of positive GAAP net income through 2025, ending its run of cash-burning quarters. That steady profit profile, paired with growth that supports Rule of 40 discipline, signals tighter capital use and better operating control. It also helped lift institutional ownership by 25% among blue-chip mutual funds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive adjuvant supply agreements with three global vaccine partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax has active adjuvant supply agreements with three global vaccine partners, and adjuvant licensing has already generated more than $40 million in milestones and royalties. That supports CpG 1018 as a platform-as-a-service asset, not just a COVID-19 input.\u003c\/p\u003e\n\u003cp\u003eThe agreements show CpG 1018 is embedded in long-term vaccines for other infectious diseases, giving Dynavax diversified revenue that can help offset any slowdown in the Hepatitis B market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax’s 2025 Surge: Revenue, Profit, and Shingles Pipeline Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax’s 2025 results were strong, led by HEPLISAV-B net product revenue of $320 million and four straight quarters of GAAP net income. The shingles Phase 3 readout hit all primary endpoints, which lifts the chance of an FDA filing by early 2027. CpG 1018 also added over $40 million from milestones and royalties.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV-B net product revenue\u003c\/td\u003e\n\u003ctd\u003e$320 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP net income streak\u003c\/td\u003e\n\u003ctd\u003e4 quarters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjuvant milestones and royalties\u003c\/td\u003e\n\u003ctd\u003eOver $40 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SOAR Analysis","offers":[{"title":"Default Title","offer_id":52938593173851,"sku":"dynavax-soar-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/6857\/8907\/files\/dynavax-soar-analysis.webp?v=1778316312","url":"https:\/\/soar-analysis.com\/products\/dynavax-soar-analysis","provider":"SOAR Analysis","version":"1.0","type":"link"}